Mitobrin (Tobramycin)

Tobramycin interferes with bacterial protein synthesis by binding to the 30S ribosomal subunit. This causes misreading of messenger RNA, leading to the production of defective proteins and bacterial cell death, especially against Gram‑negative organisms commonly found in ear infections.

The specific dose and frequency of Mitobrin are determined by the prescribing clinician based on the severity of the infection, patient age, and ear condition. Healthcare professionals tailor the regimen to achieve optimal therapeutic effect while minimizing risk.

Safety of Mitobrin in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mitobrin’s active ingredient, tobramycin, belongs to the aminoglycoside class, offering broad coverage against Gram‑negative bacteria. Compared with fluoroquinolone ear drops, tobramycin may have a higher risk of ototoxicity but is often preferred when resistant organisms are suspected or when a clinician seeks a well‑established aminoglycoside option.

Mitobrin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mitobrin is applied topically to the affected ear. The prescribed number of drops is placed into the ear canal, usually after gently cleaning the outer ear. Administration is performed by the patient or caregiver as directed by a healthcare professional.

The most serious risks include ototoxicity, which can lead to permanent hearing loss or balance problems, and systemic toxicity such as nephrotoxicity if significant absorption occurs. Severe allergic reactions, though rare, also require immediate medical attention.

Mitobrin should be avoided in individuals with a known hypersensitivity to tobramycin or other aminoglycosides, in patients with severe renal impairment unless closely monitored, and in those with pre‑existing significant hearing loss unless the benefits outweigh the risks.